TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS Share Price
Certificat
DE000SU6PZZ2
| Market Closed - Bid/Ask 20:50:58 04/06/2024 BST | ||
| 7.11 EUR | -8.26% |
|
| Current month | -14.12% | ||
| 1 month | -45.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 04/06/24 | 7.11 | -8.26% |
| 03/06/24 | 7.75 | -12.43% |
| 31/05/24 | 8.85 | -13.83% |
| 30/05/24 | 10.27 | +0.59% |
| 29/05/24 | 10.21 | +4.93% |
Real-time Boerse Frankfurt Warrants
Last update June 04, 2024 at 08:50 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU6PZZ |
| ISIN | DE000SU6PZZ2 |
| Date issued | 08/01/2024 |
| Strike | 550.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 12.55 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.06 € |
|---|---|
| Lowest since issue | 7.11 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.2
USD
Average target price
463.5
USD
Spread / Average Target
-1.41%
- Stock Market
- Certificates
- Certificat
